The Federal Circuit has upheld the decision of the Patent Trial and Appeal Board to invalidate a majority of a flu vaccine patent held by Pfizer. The decision came after careful deliberation, with the Federal Circuit confirming that the invalidation was indeed the correct course of action.
However, the appeal court did vocalize concerns around the speed at which the refusal to amend the patent was made, suggesting that the analysis may have been hasty and warranted closer examination. This signals a potential reevaluation of the patent amendment process moving forward. Despite the proposed reevaluation, Pfizer’s patent remains largely invalidated.
Further details of the Federal Circuit’s ruling can be found in the Law360 article.